Report cover image

Global Microbiome CDMO Market Analysis and Forecast 2026-2032

Publisher APO Research, Inc.
Published Jan 01, 2026
Length 190 Pages
SKU # APRC20796936

Description

The global Microbiome CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Microbiome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Microbiome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Asia-Pacific market for Microbiome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Microbiome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Microbiome CDMO include Arranta Bio, Wacker Chemie AG, Bactera, SGS Quay Pharma, Biose, EnteroBiotix, Genome And Company, Lallemand Health Solutions and List Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Microbiome CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Microbiome CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Microbiome CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Microbiome CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Microbiome CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Microbiome CDMO revenue, projected growth trends, production technology, application and end-user industry.

Microbiome CDMO Segment by Company

Arranta Bio
Wacker Chemie AG
Bactera
SGS Quay Pharma
Biose
EnteroBiotix
Genome And Company
Lallemand Health Solutions
List Bio
Rise BioServices
Lonza
MaaT Pharma
NIZO
Quay Pharmaceuticals
Recipharm

Microbiome CDMO Segment by Type

Microbial CDMO
Antibiotic CDMO
Phage CDMO
Bacteriocins CDMO

Microbiome CDMO Segment by Application

Vaccine R&D
Biopharmaceutical
Cell Therapy
Others

Microbiome CDMO Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Microbiome CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Microbiome CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome CDMO revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

190 Pages
1 Market Overview
1.1 Product Definition
1.2 Microbiome CDMO Market by Type
1.2.1 Global Microbiome CDMO Market Size by Type, 2021 VS 2025 VS 2032
1.2.2 Microbial CDMO
1.2.3 Antibiotic CDMO
1.2.4 Phage CDMO
1.2.5 Bacteriocins CDMO
1.3 Microbiome CDMO Market by Application
1.3.1 Global Microbiome CDMO Market Size by Application, 2021 VS 2025 VS 2032
1.3.2 Vaccine R&D
1.3.3 Biopharmaceutical
1.3.4 Cell Therapy
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Microbiome CDMO Market Dynamics
2.1 Microbiome CDMO Industry Trends
2.2 Microbiome CDMO Industry Drivers
2.3 Microbiome CDMO Industry Opportunities and Challenges
2.4 Microbiome CDMO Industry Restraints
3 Global Growth Perspective
3.1 Global Microbiome CDMO Market Perspective (2021-2032)
3.2 Global Microbiome CDMO Growth Trends by Region
3.2.1 Global Microbiome CDMO Market Size by Region: 2021 VS 2025 VS 2032
3.2.2 Global Microbiome CDMO Market Size by Region (2021-2026)
3.2.3 Global Microbiome CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
4.1 Global Microbiome CDMO Revenue by Players
4.1.1 Global Microbiome CDMO Revenue by Players (2021-2026)
4.1.2 Global Microbiome CDMO Revenue Market Share by Players (2021-2026)
4.1.3 Global Microbiome CDMO Players Revenue Share Top 10 and Top 5 in 2025
4.2 Global Microbiome CDMO Key Players Ranking, 2024 VS 2025 VS 2026
4.3 Global Microbiome CDMO Key Players Headquarters & Area Served
4.4 Global Microbiome CDMO Players, Product Type & Application
4.5 Global Microbiome CDMO Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Microbiome CDMO Market CR5 and HHI
4.6.3 2025 Microbiome CDMO Tier 1, Tier 2, and Tier 3
5 Microbiome CDMO Market Size by Type
5.1 Global Microbiome CDMO Revenue by Type (2021 VS 2025 VS 2032)
5.2 Global Microbiome CDMO Revenue by Type (2021-2032)
5.3 Global Microbiome CDMO Revenue Market Share by Type (2021-2032)
6 Microbiome CDMO Market Size by Application
6.1 Global Microbiome CDMO Revenue by Application (2021 VS 2025 VS 2032)
6.2 Global Microbiome CDMO Revenue by Application (2021-2032)
6.3 Global Microbiome CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
7.1 Arranta Bio
7.1.1 Arranta Bio Company Information
7.1.2 Arranta Bio Business Overview
7.1.3 Arranta Bio Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.1.4 Arranta Bio Microbiome CDMO Product Portfolio
7.1.5 Arranta Bio Recent Developments
7.2 Wacker Chemie AG
7.2.1 Wacker Chemie AG Company Information
7.2.2 Wacker Chemie AG Business Overview
7.2.3 Wacker Chemie AG Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.2.4 Wacker Chemie AG Microbiome CDMO Product Portfolio
7.2.5 Wacker Chemie AG Recent Developments
7.3 Bactera
7.3.1 Bactera Company Information
7.3.2 Bactera Business Overview
7.3.3 Bactera Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.3.4 Bactera Microbiome CDMO Product Portfolio
7.3.5 Bactera Recent Developments
7.4 SGS Quay Pharma
7.4.1 SGS Quay Pharma Company Information
7.4.2 SGS Quay Pharma Business Overview
7.4.3 SGS Quay Pharma Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.4.4 SGS Quay Pharma Microbiome CDMO Product Portfolio
7.4.5 SGS Quay Pharma Recent Developments
7.5 Biose
7.5.1 Biose Company Information
7.5.2 Biose Business Overview
7.5.3 Biose Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.5.4 Biose Microbiome CDMO Product Portfolio
7.5.5 Biose Recent Developments
7.6 EnteroBiotix
7.6.1 EnteroBiotix Company Information
7.6.2 EnteroBiotix Business Overview
7.6.3 EnteroBiotix Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.6.4 EnteroBiotix Microbiome CDMO Product Portfolio
7.6.5 EnteroBiotix Recent Developments
7.7 Genome And Company
7.7.1 Genome And Company Company Information
7.7.2 Genome And Company Business Overview
7.7.3 Genome And Company Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.7.4 Genome And Company Microbiome CDMO Product Portfolio
7.7.5 Genome And Company Recent Developments
7.8 Lallemand Health Solutions
7.8.1 Lallemand Health Solutions Company Information
7.8.2 Lallemand Health Solutions Business Overview
7.8.3 Lallemand Health Solutions Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.8.4 Lallemand Health Solutions Microbiome CDMO Product Portfolio
7.8.5 Lallemand Health Solutions Recent Developments
7.9 List Bio
7.9.1 List Bio Company Information
7.9.2 List Bio Business Overview
7.9.3 List Bio Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.9.4 List Bio Microbiome CDMO Product Portfolio
7.9.5 List Bio Recent Developments
7.10 Rise BioServices
7.10.1 Rise BioServices Company Information
7.10.2 Rise BioServices Business Overview
7.10.3 Rise BioServices Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.10.4 Rise BioServices Microbiome CDMO Product Portfolio
7.10.5 Rise BioServices Recent Developments
7.11 Lonza
7.11.1 Lonza Company Information
7.11.2 Lonza Business Overview
7.11.3 Lonza Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.11.4 Lonza Microbiome CDMO Product Portfolio
7.11.5 Lonza Recent Developments
7.12 MaaT Pharma
7.12.1 MaaT Pharma Company Information
7.12.2 MaaT Pharma Business Overview
7.12.3 MaaT Pharma Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.12.4 MaaT Pharma Microbiome CDMO Product Portfolio
7.12.5 MaaT Pharma Recent Developments
7.13 NIZO
7.13.1 NIZO Company Information
7.13.2 NIZO Business Overview
7.13.3 NIZO Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.13.4 NIZO Microbiome CDMO Product Portfolio
7.13.5 NIZO Recent Developments
7.14 Quay Pharmaceuticals
7.14.1 Quay Pharmaceuticals Company Information
7.14.2 Quay Pharmaceuticals Business Overview
7.14.3 Quay Pharmaceuticals Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.14.4 Quay Pharmaceuticals Microbiome CDMO Product Portfolio
7.14.5 Quay Pharmaceuticals Recent Developments
7.15 Recipharm
7.15.1 Recipharm Company Information
7.15.2 Recipharm Business Overview
7.15.3 Recipharm Microbiome CDMO Revenue and Gross Margin (2021-2026)
7.15.4 Recipharm Microbiome CDMO Product Portfolio
7.15.5 Recipharm Recent Developments
8 North America
8.1 North America Microbiome CDMO Revenue (2021-2032)
8.2 North America Microbiome CDMO Revenue by Type (2021-2032)
8.2.1 North America Microbiome CDMO Revenue by Type (2021-2026)
8.2.2 North America Microbiome CDMO Revenue by Type (2027-2032)
8.3 North America Microbiome CDMO Revenue Share by Type (2021-2032)
8.4 North America Microbiome CDMO Revenue by Application (2021-2032)
8.4.1 North America Microbiome CDMO Revenue by Application (2021-2026)
8.4.2 North America Microbiome CDMO Revenue by Application (2027-2032)
8.5 North America Microbiome CDMO Revenue Share by Application (2021-2032)
8.6 North America Microbiome CDMO Revenue by Country
8.6.1 North America Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032)
8.6.2 North America Microbiome CDMO Revenue by Country (2021-2026)
8.6.3 North America Microbiome CDMO Revenue by Country (2027-2032)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Microbiome CDMO Revenue (2021-2032)
9.2 Europe Microbiome CDMO Revenue by Type (2021-2032)
9.2.1 Europe Microbiome CDMO Revenue by Type (2021-2026)
9.2.2 Europe Microbiome CDMO Revenue by Type (2027-2032)
9.3 Europe Microbiome CDMO Revenue Share by Type (2021-2032)
9.4 Europe Microbiome CDMO Revenue by Application (2021-2032)
9.4.1 Europe Microbiome CDMO Revenue by Application (2021-2026)
9.4.2 Europe Microbiome CDMO Revenue by Application (2027-2032)
9.5 Europe Microbiome CDMO Revenue Share by Application (2021-2032)
9.6 Europe Microbiome CDMO Revenue by Country
9.6.1 Europe Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032)
9.6.2 Europe Microbiome CDMO Revenue by Country (2021-2026)
9.6.3 Europe Microbiome CDMO Revenue by Country (2027-2032)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Microbiome CDMO Revenue (2021-2032)
10.2 China Microbiome CDMO Revenue by Type (2021-2032)
10.2.1 China Microbiome CDMO Revenue by Type (2021-2026)
10.2.2 China Microbiome CDMO Revenue by Type (2027-2032)
10.3 China Microbiome CDMO Revenue Share by Type (2021-2032)
10.4 China Microbiome CDMO Revenue by Application (2021-2032)
10.4.1 China Microbiome CDMO Revenue by Application (2021-2026)
10.4.2 China Microbiome CDMO Revenue by Application (2027-2032)
10.5 China Microbiome CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
11.1 Asia Microbiome CDMO Revenue (2021-2032)
11.2 Asia Microbiome CDMO Revenue by Type (2021-2032)
11.2.1 Asia Microbiome CDMO Revenue by Type (2021-2026)
11.2.2 Asia Microbiome CDMO Revenue by Type (2027-2032)
11.3 Asia Microbiome CDMO Revenue Share by Type (2021-2032)
11.4 Asia Microbiome CDMO Revenue by Application (2021-2032)
11.4.1 Asia Microbiome CDMO Revenue by Application (2021-2026)
11.4.2 Asia Microbiome CDMO Revenue by Application (2027-2032)
11.5 Asia Microbiome CDMO Revenue Share by Application (2021-2032)
11.6 Asia Microbiome CDMO Revenue by Country
11.6.1 Asia Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032)
11.6.2 Asia Microbiome CDMO Revenue by Country (2021-2026)
11.6.3 Asia Microbiome CDMO Revenue by Country (2027-2032)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Microbiome CDMO Revenue (2021-2032)
12.2 SAMEA Microbiome CDMO Revenue by Type (2021-2032)
12.2.1 SAMEA Microbiome CDMO Revenue by Type (2021-2026)
12.2.2 SAMEA Microbiome CDMO Revenue by Type (2027-2032)
12.3 SAMEA Microbiome CDMO Revenue Share by Type (2021-2032)
12.4 SAMEA Microbiome CDMO Revenue by Application (2021-2032)
12.4.1 SAMEA Microbiome CDMO Revenue by Application (2021-2026)
12.4.2 SAMEA Microbiome CDMO Revenue by Application (2027-2032)
12.5 SAMEA Microbiome CDMO Revenue Share by Application (2021-2032)
12.6 SAMEA Microbiome CDMO Revenue by Country
12.6.1 SAMEA Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032)
12.6.2 SAMEA Microbiome CDMO Revenue by Country (2021-2026)
12.6.3 SAMEA Microbiome CDMO Revenue by Country (2027-2032)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.